Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Equity: 2018-2019

Historic Return on Equity for Monopar Therapeutics (MNPR) over the last 2 years, with Dec 2019 value amounting to -0.50%.

  • Monopar Therapeutics' Return on Equity fell 7.00% to -0.50% in Q4 2019 from the same period last year, while for Dec 2019 it was -0.50%, marking a year-over-year decrease of 7.00%. This contributed to the annual value of -0.44% for FY2019, which is 4.00% down from last year.
  • Per Monopar Therapeutics' latest filing, its Return on Equity stood at -0.50% for Q4 2019, which was up 39.29% from -0.83% recorded in Q3 2019.
  • Monopar Therapeutics' Return on Equity's 5-year high stood at -0.38% during Q3 2018, with a 5-year trough of -2.03% in Q2 2018.
  • In the last 2 years, Monopar Therapeutics' Return on Equity had a median value of -0.65% in 2019 and averaged -0.92%.
  • Examining YoY changes over the last 5 years, Monopar Therapeutics' Return on Equity showed a top increase of 130bps in 2019 and a maximum decrease of 45bps in 2019.
  • Monopar Therapeutics' Return on Equity (Quarterly) stood at -0.44% in 2018, then declined by 7bps to -0.50% in 2019.
  • Its Return on Equity was -0.50% in Q4 2019, compared to -0.83% in Q3 2019 and -0.72% in Q2 2019.